Caption Management, LLC Avadel Pharmaceuticals PLC Call Options Transaction History

Caption Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$5.02 - $10.0 $276,100 - $550,000	55,000 New	55,000 $393,000
Q1 2022 May 13, 2022	SELL	$5.46 - $8.29 $403,494 - $612,630	-73,900 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$7.34 - $11.18 $3.68 Million - $5.6 Million	-501,100 Reduced 87.15%	73,900 $597,000
Q3 2021 Nov 12, 2021	BUY	$6.49 - $9.91 $3.57 Million - $5.45 Million	550,000 Added 2200.0%	575,000 $5.64 Million
Q2 2021 Aug 16, 2021	SELL	$6.73 - $9.05 $168,250 - $226,250	-25,000 Reduced 50.0%	25,000 $168,000
Q2 2020 Aug 14, 2020	SELL	$7.25 - $11.75 $2.66 Million - $4.31 Million	-367,200 Reduced 88.02%	50,000 $405,000
Q1 2020 May 15, 2020	BUY	$4.06 - $10.64 $1.69 Million - $4.44 Million	417,200 New	417,200 $3.31 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.